GNPX 2017 Annual Report

27 The following table shows our families of issued patents and patent applications, together with information about the type of patent protection, the jurisdiction and the patent expiration dates. Patent Family Title and (Description) Type of Patent Protection Jurisdiction Patent Expiration Dates 1 Chromosome 3p21.3 genes are tumor suppressors (Use of our platform genes, including TUSC2, and use of our non-viral nanovesicle delivery system) The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions United States (2 issued) United States (1 pending) Australia (2 issued) Japan (1 issued) Canada (1 issued) Europe (1 issued; validated in Switzerland, Germany, Denmark, Finland, France, United Kingdom, Ireland, Sweden, Netherlands) 7/10/2021, except for the issued US patents, which expire on 5/15/2024 and 7/29/2022 2 Bioactive FUS1 Peptides and Nanoparticle-Polypeptide Complexes (Pharmaceutical formulation of TUSC2 (also referred to as FUS1) nanoparticles, method of delivering TUSC2 to cancer cells, and method of treating cancer patients with TUSC2 nanoparticles) The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions United States (2 issued) Korea (1 issued) 1/23/2030, 3/14/2026 7/29/2022 3 Methods and Compositions of Non- Viral Gene Therapy for Treatment of Hyperproliferative Diseases (Methods of delivery, including our nanovesicle delivery system, of a series of genes that are licensed to us, including TUSC2, and genes that are not licensed to us) The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions United States (1 pending) Canada (1 issued) Europe (1 issued) Belgium (1 issued) France (1 issued) Germany (1 issued) Italy (1 issued) Liechtenstein (1 issued) Spain (1 issued) Sweden (1 issued) Switzerland (1 issued) United Kingdom (1 issued) 5/24/2020 4 Methods and Compositions Related to Novel hTMC Promoter and Vectors for Tumor-Selective and High- Efficient Expression of Therapeutic Genes (A genetic technology to improve the effectiveness of gene therapy, relating to our platform genes and other genes) The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions United States (1 issued) 8/24/2029 Because the use of our platform genes, including TUSC2, and the use of our non-viral delivery system to deliver them, are covered by Family No. 1, we believe that expiration of the patents in Family 3 will not affect our intellectual property protection for use of the genes which are licensed to us and are part of our platform. We also hold a non-exclusive license from the National Institutes of Health to 15 patents that expired on August 1, 2017. We are aware that others have also licensed these technologies from the NIH. These patents relate to the DOTAP:cholesterol liposomes for delivery of therapeutic DNA, which is the basic delivery system embodied in our nanovesicles. Through our license from MD Anderson, we have separate patent protection for the combination of our nanovesicles with the genes we have licensed from MD Anderson, as well as for improvements that MD Anderson has made to the nanovesicle delivery system. Because the license from the NIH is non-exclusive, we do not expect the expiration of the underlying patents to have a material effect on our business. We have an ongoing obligation to pay the NIH a total of $240,000 (together with an additional $20,000 each year starting in 2018) upon our receipt of regulatory approval for our current or potential product candidates. In addition to the current licensed patents, Genprex is currently evaluating additional patent licenses from MD Anderson to add to the patent portfolio and expand our commercial potential. We expect to evaluate technology transfer opportunities to leverage the commercial potential of our platform delivery system and also seek complementary oncology therapies.